JP2017518348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518348A5 JP2017518348A5 JP2016574004A JP2016574004A JP2017518348A5 JP 2017518348 A5 JP2017518348 A5 JP 2017518348A5 JP 2016574004 A JP2016574004 A JP 2016574004A JP 2016574004 A JP2016574004 A JP 2016574004A JP 2017518348 A5 JP2017518348 A5 JP 2017518348A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- optionally substituted
- disorder
- cancer
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 22
- 230000001684 chronic effect Effects 0.000 claims description 18
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 16
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 14
- -1 Benzotriazinyl Chemical group 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 125000003107 substituted aryl group Chemical group 0.000 claims description 13
- 206010020751 Hypersensitivity Diseases 0.000 claims description 12
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 12
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 208000026935 allergic disease Diseases 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 208000020084 Bone disease Diseases 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 8
- 108090000190 Thrombin Proteins 0.000 claims description 8
- 230000030833 cell death Effects 0.000 claims description 8
- 230000001066 destructive effect Effects 0.000 claims description 8
- 208000016361 genetic disease Diseases 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 208000030159 metabolic disease Diseases 0.000 claims description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 8
- 229960004072 thrombin Drugs 0.000 claims description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 230000007170 pathology Effects 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 6
- 208000015943 Coeliac disease Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims description 6
- 101150053046 MYD88 gene Proteins 0.000 claims description 6
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 206010047115 Vasculitis Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 6
- 201000009890 sinusitis Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 5
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 5
- 201000002481 Myositis Diseases 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 5
- 201000008383 nephritis Diseases 0.000 claims description 5
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 201000011152 Pemphigus Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 3
- 206010001889 Alveolitis Diseases 0.000 claims description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 206010003011 Appendicitis Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000023611 Burkitt leukaemia Diseases 0.000 claims description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 3
- 208000006029 Cardiomegaly Diseases 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 241001317099 Dystaxia Species 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- 201000011275 Epicondylitis Diseases 0.000 claims description 3
- 206010016228 Fasciitis Diseases 0.000 claims description 3
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 3
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000022461 Glomerular disease Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000003807 Graves Disease Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 3
- 206010023347 Keratoacanthoma Diseases 0.000 claims description 3
- 201000008197 Laryngitis Diseases 0.000 claims description 3
- 206010024238 Leptospirosis Diseases 0.000 claims description 3
- 208000004852 Lung Injury Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 206010028289 Muscle atrophy Diseases 0.000 claims description 3
- 208000003926 Myelitis Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 3
- 208000005141 Otitis Diseases 0.000 claims description 3
- 208000027868 Paget disease Diseases 0.000 claims description 3
- 206010034277 Pemphigoid Diseases 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- 208000007452 Plasmacytoma Diseases 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 206010036774 Proctitis Diseases 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 201000010208 Seminoma Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 3
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 208000000491 Tendinopathy Diseases 0.000 claims description 3
- 206010043255 Tendonitis Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 208000006374 Uterine Cervicitis Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010069351 acute lung injury Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 208000004631 alopecia areata Diseases 0.000 claims description 3
- 230000036783 anaphylactic response Effects 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 3
- 230000001925 catabolic effect Effects 0.000 claims description 3
- 206010008323 cervicitis Diseases 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 208000003167 cholangitis Diseases 0.000 claims description 3
- 201000001352 cholecystitis Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 claims description 3
- 208000007784 diverticulitis Diseases 0.000 claims description 3
- 208000019258 ear infection Diseases 0.000 claims description 3
- 210000003981 ectoderm Anatomy 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 206010014665 endocarditis Diseases 0.000 claims description 3
- 230000002124 endocrine Effects 0.000 claims description 3
- 210000003979 eosinophil Anatomy 0.000 claims description 3
- 210000000918 epididymis Anatomy 0.000 claims description 3
- 201000010063 epididymitis Diseases 0.000 claims description 3
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 208000030941 fetal growth restriction Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 230000003325 follicular Effects 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 231100000852 glomerular disease Toxicity 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000007475 hemolytic anemia Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims description 3
- 210000004276 hyalin Anatomy 0.000 claims description 3
- 206010020718 hyperplasia Diseases 0.000 claims description 3
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 3
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims description 3
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 206010023332 keratitis Diseases 0.000 claims description 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000011486 lichen planus Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 231100000515 lung injury Toxicity 0.000 claims description 3
- 208000027202 mammary Paget disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000004396 mastitis Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000000585 muscular atrophy Diseases 0.000 claims description 3
- 208000009928 nephrosis Diseases 0.000 claims description 3
- 231100001027 nephrosis Toxicity 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 206010057056 paraneoplastic pemphigus Diseases 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 208000008494 pericarditis Diseases 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 206010034674 peritonitis Diseases 0.000 claims description 3
- 208000001297 phlebitis Diseases 0.000 claims description 3
- 208000008423 pleurisy Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 201000007094 prostatitis Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 208000003265 stomatitis Diseases 0.000 claims description 3
- 201000004595 synovitis Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 201000004415 tendinitis Diseases 0.000 claims description 3
- 210000001550 testis Anatomy 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 206010044008 tonsillitis Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 3
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 208000004145 Endometritis Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010034038 Parotitis Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000003416 augmentation Effects 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 201000008319 inclusion body myositis Diseases 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 230000002062 proliferating effect Effects 0.000 claims 6
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 2
- 206010015218 Erythema multiforme Diseases 0.000 claims 2
- 206010037596 Pyelonephritis Diseases 0.000 claims 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 210000003905 vulva Anatomy 0.000 claims 2
- 206010005149 Blepharitis allergic Diseases 0.000 claims 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims 1
- 206010031149 Osteitis Diseases 0.000 claims 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 241000519995 Stachys sylvatica Species 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000018339 bone inflammation disease Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000000281 joint capsule Anatomy 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 210000004561 lacrimal apparatus Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 210000003681 parotid gland Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 0 C*(C(NNC(C)(C)*)=O)C1=CC2*=*=C(CC3=C=N3)C2C=C1* Chemical compound C*(C(NNC(C)(C)*)=O)C1=CC2*=*=C(CC3=C=N3)C2C=C1* 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010062639 Herpes dermatitis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3017CH2014 | 2014-06-20 | ||
| IN3017/CHE/2014 | 2014-06-20 | ||
| PCT/IB2015/054620 WO2015193846A1 (en) | 2014-06-20 | 2015-06-19 | Substituted indazole compounds as irak4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017518348A JP2017518348A (ja) | 2017-07-06 |
| JP2017518348A5 true JP2017518348A5 (enExample) | 2018-08-02 |
Family
ID=54934936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574004A Pending JP2017518348A (ja) | 2014-06-20 | 2015-06-19 | Ｉｒａｋ４阻害剤としての置換インダゾール化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170152263A1 (enExample) |
| EP (1) | EP3157521A4 (enExample) |
| JP (1) | JP2017518348A (enExample) |
| KR (1) | KR20170016500A (enExample) |
| CN (1) | CN106456609A (enExample) |
| AU (1) | AU2015275730A1 (enExample) |
| BR (1) | BR112016029853A2 (enExample) |
| CA (1) | CA2952188A1 (enExample) |
| CU (1) | CU20160188A7 (enExample) |
| EA (1) | EA201692418A1 (enExample) |
| HK (1) | HK1231411A1 (enExample) |
| IL (1) | IL249345A0 (enExample) |
| MX (1) | MX2016017147A (enExample) |
| PH (1) | PH12016502382A1 (enExample) |
| SG (1) | SG11201610009XA (enExample) |
| WO (1) | WO2015193846A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311677B2 (en) | 2014-01-13 | 2025-06-01 | Aurigene Oncology Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| WO2016174183A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| EP3195865A1 (de) | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Kombinationen von irak4 inhibitoren und btk inhibitoren |
| CA2992406A1 (en) * | 2015-07-15 | 2017-01-19 | Aurigene Discovery Technologies Limited | Indazole and azaindazole compounds as irak-4 inhibitors |
| EP3394066A2 (en) | 2015-12-22 | 2018-10-31 | H. Hoffnabb-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| US10435396B2 (en) | 2016-03-03 | 2019-10-08 | Bayer Pharma Aktiegesellschaft | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| WO2017207386A1 (de) | 2016-06-01 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen |
| SI3464266T1 (sl) | 2016-06-01 | 2021-12-31 | Bayer Animal Health Gmbh | Substituirani indazoli, uporabni pri zdravljenju in preprečevanju alergijskih in/ali vnetnih bolezni pri živalih |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| AR109596A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos pirazolopiridina y sus usos |
| WO2018083085A1 (en) | 2016-11-02 | 2018-05-11 | F. Hoffmann-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| CN120267671A (zh) | 2017-03-31 | 2025-07-08 | 奥锐金肿瘤有限公司 | 用于治疗血液病的化合物和组合物 |
| JP2020524692A (ja) * | 2017-06-21 | 2020-08-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｉｒａｋ４調節因子としてのベンゾフラン |
| CN110785418A (zh) | 2017-06-21 | 2020-02-11 | 豪夫迈·罗氏有限公司 | 作为irak4调节剂的异二氢吲哚酮衍生物 |
| WO2018234345A1 (en) | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | PYRAZOLO [1,5A] PYRIMIDINE DERIVATIVES AS MODULATORS OF IRAK4 |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| EP4410377A3 (en) | 2017-10-31 | 2024-11-13 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| CA3090275A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| DK3755703T3 (da) | 2018-02-20 | 2022-06-27 | Incyte Corp | N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| EP3774797B1 (en) * | 2018-04-05 | 2025-11-19 | Merck Patent GmbH | Heteroaryl compounds as type ii irak inhibitors and uses hereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| CN110833559A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗急性肺损伤致肺纤维化的用途 |
| WO2020035019A1 (zh) | 2018-08-17 | 2020-02-20 | 浙江海正药业股份有限公司 | 吲唑胺类衍生物及其制备方法和其在医药上的用途 |
| CN112654604B (zh) * | 2018-09-06 | 2023-05-16 | 浙江海正药业股份有限公司 | 7-取代吲唑类衍生物及其制备方法和其在医药上的用途 |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| JP7620611B2 (ja) | 2019-07-18 | 2025-01-23 | ブリストル－マイヤーズ スクイブ カンパニー | ＩＲＡＫ４阻害剤として有用なピラゾロ［３，４－ｄ］ピロロ［１，２－ｂ］ピリダジニル化合物 |
| KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
| WO2021047677A1 (zh) * | 2019-09-12 | 2021-03-18 | 中国科学院上海药物研究所 | 一类irak4激酶抑制剂及其制备和应用 |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| CN115867562A (zh) * | 2020-05-08 | 2023-03-28 | 乔治穆内有限责任公司 | Akt3调节剂 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| MX2023001445A (es) * | 2020-08-04 | 2023-05-08 | Aurigene Oncology Ltd | Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4. |
| WO2022135338A1 (zh) * | 2020-12-25 | 2022-06-30 | 南京明德新药研发有限公司 | 酰胺噁唑类化合物 |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| CA3214747A1 (en) | 2021-04-08 | 2022-10-13 | Reinhard Von Roemeling | Combination therapies for the treatment of cancer |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| TW202330546A (zh) * | 2021-12-31 | 2023-08-01 | 香港商愛科諾生物醫藥(香港)有限公司 | 具有irak4抑制活性的化合物，包含其的藥物組合物，及其應用 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1181327A (en) * | 1915-08-10 | 1916-05-02 | Michael F Mcandrew | Basket construction and guard therefor. |
| US1301085A (en) * | 1916-11-06 | 1919-04-15 | Charles R Hadley Company | Loose-leaf binder. |
| AU649421B2 (en) * | 1990-05-18 | 1994-05-26 | Sanofi-Aventis Deutschland Gmbh | Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs |
| DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| US20030134836A1 (en) * | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| DE10162375A1 (de) * | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
| EP1617840A4 (en) * | 2003-05-01 | 2008-08-20 | Bristol Myers Squibb Co | PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS |
| ATE556067T1 (de) * | 2003-05-20 | 2012-05-15 | Ajinomoto Kk | Modulatoren des vanilloid rezeptors |
| US20050004133A1 (en) * | 2003-06-05 | 2005-01-06 | Makings Lewis R. | Modulators of VR1 receptor |
| WO2005034870A2 (en) * | 2003-10-07 | 2005-04-21 | Renovis, Inc. | Amide compounds and ion channel ligands and uses thereof |
| CN102633783A (zh) * | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| NZ575410A (en) * | 2006-09-07 | 2012-03-30 | Biogen Idec Inc | 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives |
| JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| JP5364875B2 (ja) * | 2007-07-16 | 2013-12-11 | アッヴィ・インコーポレイテッド | タンパク質キナーゼ阻害薬としてのインダゾール類、ベンゾイソオキサゾール類およびベンゾイソチアゾール類 |
| JP5496915B2 (ja) * | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| ES2749504T3 (es) * | 2009-10-13 | 2020-03-20 | Ligand Pharm Inc | Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos |
| US8822447B2 (en) * | 2010-04-22 | 2014-09-02 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
| US20130053382A1 (en) * | 2010-04-30 | 2013-02-28 | Sunil Paliwal | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) |
| DK2585064T3 (en) * | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| KR20140077963A (ko) * | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| GB201119401D0 (en) * | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| HK1231480A1 (zh) * | 2014-01-10 | 2017-12-22 | Aurigene Discovery Technologies Limited | 作为irak4抑制剂的吲唑化合物 |
| MX2016010056A (es) * | 2014-02-06 | 2016-11-15 | Abbvie Inc | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
-
2015
- 2015-06-19 CA CA2952188A patent/CA2952188A1/en not_active Abandoned
- 2015-06-19 SG SG11201610009XA patent/SG11201610009XA/en unknown
- 2015-06-19 US US15/320,111 patent/US20170152263A1/en not_active Abandoned
- 2015-06-19 MX MX2016017147A patent/MX2016017147A/es unknown
- 2015-06-19 EA EA201692418A patent/EA201692418A1/ru unknown
- 2015-06-19 KR KR1020177001487A patent/KR20170016500A/ko not_active Withdrawn
- 2015-06-19 CN CN201580033142.0A patent/CN106456609A/zh active Pending
- 2015-06-19 BR BR112016029853A patent/BR112016029853A2/pt not_active IP Right Cessation
- 2015-06-19 JP JP2016574004A patent/JP2017518348A/ja active Pending
- 2015-06-19 EP EP15809538.0A patent/EP3157521A4/en not_active Withdrawn
- 2015-06-19 WO PCT/IB2015/054620 patent/WO2015193846A1/en not_active Ceased
- 2015-06-19 CU CUP2016000188A patent/CU20160188A7/es unknown
- 2015-06-19 HK HK17105243.5A patent/HK1231411A1/zh unknown
- 2015-06-19 AU AU2015275730A patent/AU2015275730A1/en not_active Abandoned
-
2016
- 2016-11-29 PH PH12016502382A patent/PH12016502382A1/en unknown
- 2016-12-01 IL IL249345A patent/IL249345A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024201172B2 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| JP2017505337A5 (enExample) | ||
| ES2927104T3 (es) | Derivados de pirazolopiridina como moduladores de HPK1 y usos de los mismos para el tratamiento del cáncer | |
| JP2017502088A5 (enExample) | ||
| ES2975436T3 (es) | Enantiómeros (R) y (S) de n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4- il)oxazol-carboxamida como inhibidores de IRAK4 para el tratamiento del cáncer | |
| CN105263931B (zh) | 作为fgfr抑制剂的双环杂环 | |
| CN115557933B (zh) | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 | |
| AU2012363558B2 (en) | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases | |
| BR112021007679A2 (pt) | inibidores de tyk2 e seus usos | |
| JP2023529108A (ja) | インダゾール誘導体ならびにその調製方法および応用 | |
| JP2022166179A (ja) | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス | |
| CA3015484A1 (en) | Novel condensed pyrimidine compound or salt thereof | |
| AU2016293441A1 (en) | Indazole and azaindazole compounds as IRAK-4 inhibitors | |
| AU2010219466A1 (en) | Pyrrolopyrimidines used as kinase inhibitors | |
| AU2015402778B2 (en) | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | |
| JP2016531870A5 (enExample) | ||
| CN110229142A (zh) | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 | |
| JP2020525512A (ja) | 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物 | |
| PT2074120E (pt) | Compostos de tropano | |
| US11753418B2 (en) | Compounds for the modulation of Myc activity | |
| KR20200134179A (ko) | N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
| AU2024321427A1 (en) | Pharmaceutical compounds and compositions as c-kit kinase inhibitors | |
| CA3240011A1 (en) | Fused thiazolopyrimidine derivatives as mnks inhibitors | |
| JP2019514951A (ja) | 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体 | |
| CA3192158A1 (en) | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds |